Conservest Capital Advisors Inc. Makes New $132,000 Investment in Fractyl Health, Inc. (NASDAQ:GUTS)

Conservest Capital Advisors Inc. acquired a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 64,118 shares of the company’s stock, valued at approximately $132,000. Conservest Capital Advisors Inc. owned about 0.13% of Fractyl Health at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of GUTS. Jane Street Group LLC purchased a new position in Fractyl Health during the 3rd quarter worth $25,000. Parkside Financial Bank & Trust purchased a new position in shares of Fractyl Health in the 4th quarter worth about $27,000. JPMorgan Chase & Co. boosted its holdings in shares of Fractyl Health by 335.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock worth $37,000 after buying an additional 11,406 shares during the last quarter. HighTower Advisors LLC purchased a new position in shares of Fractyl Health in the 3rd quarter worth about $38,000. Finally, Beta Wealth Group Inc. purchased a new position in shares of Fractyl Health in the 3rd quarter worth about $44,000.

Insider Buying and Selling

In related news, CEO Harith Rajagopalan sold 90,972 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the sale, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $894,218.78. The trade was a 15.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.81, for a total value of $40,446.26. Following the completion of the sale, the insider now owns 153,544 shares in the company, valued at $277,914.64. This represents a 12.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Ratings Changes

Separately, Morgan Stanley cut their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS opened at $1.56 on Friday. The company’s 50-day moving average is $1.78 and its 200 day moving average is $2.29. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The company has a market capitalization of $75.03 million and a P/E ratio of -0.13. Fractyl Health, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $10.50.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.